Evogene (NASDAQ:EVGN) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Evogene Ltd. (NASDAQ:EVGN) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.11 and traded as low as $0.7423. Evogene shares last traded at $0.8090, with a volume of 1,080,831 shares changing hands.

Evogene Stock Down 1.4%

The firm has a market cap of $4.28 million, a PE ratio of -0.68 and a beta of 1.36. The company has a 50-day simple moving average of $0.97 and a two-hundred day simple moving average of $1.11.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, March 5th. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.35). The business had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.28 million. Evogene had a negative net margin of 214.57% and a negative return on equity of 121.44%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EVGN. XTX Topco Ltd purchased a new stake in shares of Evogene during the 4th quarter worth approximately $25,000. Citadel Advisors LLC lifted its stake in Evogene by 169.4% in the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 36,206 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in Evogene by 58.0% in the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,387 shares during the last quarter. 10.40% of the stock is currently owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.